在先进的人类恶性瘤中,使用复合性互白素-2和干扰素α2b进行家庭治疗
J Atzpodien1, A Körfer, C R Franks
1Department of Haematology and Oncology, M.H.H. University Medical Center, Hannover, West Germany.
Lancet (London, England)
|June 23, 1990
概括
在先进的癌症患者中,在家中自注射复合人间白蛋白-2 (rIL-2) 和干扰素-α2b (IFN-α2b) 的安全性和有效性得到证明. 这种疗法显示了与有毒静脉注射疗法相似的响应率.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 药理学 药理学是指药理学的学科.
背景情况:
- 晚期癌症往往会对标准治疗产生耐药性.
- 介质素-2 (IL-2) 和介质素-α (IFN-α) 是免疫治疗剂.
- 高剂量静脉注射IL-2疗法是有效的,但有毒,需要住院治疗.
研究的目的:
- 评估一种新型家庭治疗方案的安全性,耐受性和临床效应.
- 评估复合人间白蛋白-2 (rIL-2) 和干扰素-α2b (IFN-α2b) 的皮下自给药.
- 将结果与现有的静脉注射治疗先进癌症的结果进行比较.
主要方法:
- 35名患有晚期,耐火性癌症的患者接受了52个治疗周期.
- 治疗方案包括为期2天的rIL-2脉冲,随后为期6周的联合rIL-2和IFN-alpha 2b.
- 自我注射是通过皮下注射进行的.
主要成果:
- 在大多数患者中,该疗法总体上是安全的,耐受性良好,并具有轻度至中度的不良反应 (WHO等级I-II).
- 常见的副作用包括发烧,寒,恶心,厌食症和低血压.
- 没有发生与治疗相关的死亡.
- 细胞癌患者的反应率与有毒的,住院患者静脉注射IL-2疗法相比较.
结论:
- 皮下自我管理的rIL-2和IFN-alpha 2b提供了一个安全和耐受的家庭治疗选择,用于晚期的癌症.
- 这种方案的疗效与高剂量静脉注射IL-2的疗效相当,有可能改善患者的便利性并减少医疗保健负担.
- 需要进一步的研究来优化剂量和扩大这种家庭免疫疗法的患者群体.
相关概念视频
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...